Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Pancreatic cancer is a highly lethal malignancy with limited effective treatment options.
• Current targeted therapies are often ineffective due to tumor heterogeneity and the inability to address broad signaling pathway modifications.
• Multimodal therapeutic strategies are needed to simultaneously target multiple signaling pathways for improved treatment outcomes.

Purpose of the Study:

• To investigate the potential of small interfering RNAs (siRNAs) as a multimodal therapeutic strategy for pancreatic cancer.
• To assess the efficacy of siRNAs targeting KRAS and apoptosis-associated genes (BCLXL, FLIP, MCL1L, SURVIVIN, XIAP) in vitro and in vivo.

Main Methods:

• Transfection of human and murine pancreatic cancer cell lines with siRNAs against KRAS and key apoptosis-associated genes.
• Measurement of apoptosis induction via Caspase 3/7 activation, subG1 FACS analysis, and PARP cleavage.
• Evaluation of the therapeutic approach in a subcutaneous allograft model using a murine cancer cell line.

Main Results:

• siRNAs demonstrated significant inhibition of proliferation and induction of apoptosis in pancreatic cancer cells both in vitro and in vivo.
• The systematic remodeling of signal transduction using siRNAs proved effective in controlling tumor growth.
• Successful induction of apoptosis was confirmed through multiple assays, including Caspase 3/7 activation and PARP cleavage.

Conclusions:

• siRNAs are suitable tools for modeling multimodal therapy against signaling pathways in pancreatic cancer.
• Targeting multiple genes simultaneously with siRNAs shows promise for improving treatment efficacy.
• Advancements in in vivo delivery of siRNAs against multiple targets could represent a potential future therapeutic approach for pancreatic cancer.